Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

619 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.
Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, Miller VA, Stephens PJ, Rimm DL, Gómez H, Chang JC, Sanders ME, Cook RS, Arteaga CL. Balko JM, et al. Among authors: combs se. Sci Transl Med. 2016 Apr 13;8(334):334ra53. doi: 10.1126/scitranslmed.aad3001. Sci Transl Med. 2016. PMID: 27075627 Free PMC article.
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM. Loi S, et al. Clin Cancer Res. 2016 Mar 15;22(6):1499-509. doi: 10.1158/1078-0432.CCR-15-1125. Epub 2015 Oct 29. Clin Cancer Res. 2016. PMID: 26515496 Free PMC article.
Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM. Loi S, et al. Clin Cancer Res. 2019 Feb 15;25(4):1437. doi: 10.1158/1078-0432.CCR-18-4264. Clin Cancer Res. 2019. PMID: 30770496 No abstract available.
Loss of antigenicity with tissue age in breast cancer.
Combs SE, Han G, Mani N, Beruti S, Nerenberg M, Rimm DL. Combs SE, et al. Lab Invest. 2016 Mar;96(3):264-9. doi: 10.1038/labinvest.2015.138. Epub 2015 Nov 16. Lab Invest. 2016. PMID: 26568292 Free article.
Radiomics-based prediction of local control in patients with brain metastases following postoperative stereotactic radiotherapy.
Buchner JA, Kofler F, Mayinger M, Christ SM, Brunner TB, Wittig A, Menze B, Zimmer C, Meyer B, Guckenberger M, Andratschke N, El Shafie RA, Debus J, Rogers S, Riesterer O, Schulze K, Feldmann HJ, Blanck O, Zamboglou C, Ferentinos K, Bilger-Zähringer A, Grosu AL, Wolff R, Piraud M, Eitz KA, Combs SE, Bernhardt D, Rueckert D, Wiestler B, Peeken JC. Buchner JA, et al. Among authors: combs se. Neuro Oncol. 2024 May 30:noae098. doi: 10.1093/neuonc/noae098. Online ahead of print. Neuro Oncol. 2024. PMID: 38813990
Development and benchmarking of a Deep Learning-based MRI-guided gross tumor segmentation algorithm for Radiomics analyses in extremity soft tissue sarcomas.
Peeken JC, Etzel L, Tomov T, Münch S, Schüttrumpf L, Shaktour JH, Kiechle J, Knebel C, Schaub SK, Mayr NA, Woodruff HC, Lambin P, Gersing AS, Bernhardt D, Nyflot MJ, Menze B, Combs SE, Navarro F. Peeken JC, et al. Among authors: combs se. Radiother Oncol. 2024 May 22;197:110338. doi: 10.1016/j.radonc.2024.110338. Online ahead of print. Radiother Oncol. 2024. PMID: 38782301 Free article.
Carbon ion radiotherapy of hepatocellular carcinoma provides excellent local control: The prospective phase I PROMETHEUS trial.
Hoegen-Saßmannshausen P, Naumann P, Hoffmeister-Wittmann P, Ben Harrabi S, Seidensaal K, Weykamp F, Mielke T, Ellerbrock M, Habermehl D, Springfeld C, Dill MT, Longerich T, Schirmacher P, Mehrabi A, Chang DH, Hörner-Rieber J, Jäkel O, Haberer T, Combs SE, Debus J, Herfarth K, Liermann J. Hoegen-Saßmannshausen P, et al. Among authors: combs se. JHEP Rep. 2024 Mar 11;6(6):101063. doi: 10.1016/j.jhepr.2024.101063. eCollection 2024 Jun. JHEP Rep. 2024. PMID: 38737600 Free PMC article.
619 results